CXCL10 and type 1 diabetes mellitus: Co-therapy with anti-CD3 and anti-CXCL10 showed promising results in animal models of T1D, by preventing some immune cell infiltration into the islets, but neutralization of one chemokine alone may not be sufficient in a disease where many chemokines have overlapping functions.48, 62 By administering anti-MT treatment along with anti-CD3, autoreactive T cells would be diminished, and T cell development would resume in an environment less rich in MT and its proinflammatory effects.